E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The trial will include participants with Xerostomia (International Classification of Diseases-10: DQ 838A) who have been treated with raditherapy for a head and neck cancer prevoiusly. |
Studiet vil inkludere forsøgsdeltagere med xerostomi (DQ 838A) efter tidligere strålebahandling af en hovedhalskræft. |
|
E.1.1.1 | Medical condition in easily understood language |
This trial will include participants with dry-mouth after radiation therapy and head and neck cancer. |
Studiet vil inkludere deltagere med mundtørhed efter strålebehandling for hovedhalskræft. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10013781 |
E.1.2 | Term | Dry mouth |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048223 |
E.1.2 | Term | Xerostomia |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10039420 |
E.1.2 | Term | Salivary gland therapeutic procedures |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10039404 |
E.1.2 | Term | Salivary gland conditions |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10039390 |
E.1.2 | Term | Salivary gland atrophy |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective is to examine whether enrichment of the submandibular glands with injections of allogeneic ASCs will improve the salivary function in radiation-induced salivary damage. |
Formålet er at undersøge om donor fedtstamceller kan forbedre funktion af spytkirler, der er blevet beskadiget i forbindelse med strålebehandling for hovedhalskræft. |
|
E.2.2 | Secondary objectives of the trial |
Screening of changes in quality of life and immune response secondary to treatment with allogeneic adipose-derived mesenchymal stem cells. Further the objective is to investigate whether repeated treatment witj allogenic ASCs is better than a single treatment. |
Screening af ændringer i livskvaliteten og screening ændringer i recipientens immunforsvar secondært til behandling med allogene fedt-deriverede mesekymale stamceller. Formålet er desuden at undersøge om gentagen behandling med donorstamceller har bedre effekt på spytkirtelfunktionen end en enkelt behandling. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Repeated treatmen with ASCs in patients who have previously received ASCs as part of MESRIX-I, MESRIX-II or MESRIX-III. The objective is to investigate whether repeated treatment witj allogenic ASCs is better than a single treatment. Inclusion criteria: 1. Previous treatment with ASCs in the salivary glands as part of MESRIX-I, MESRIX-II or MESRIX-III. 2. WHO Performance status (PS) 0-1 64 3. Age between 18-75 years 4. 2 years’ follow-up for their head and neck cancer without recurrence 5. Informed consent.
Additional exclusion criteria: 1. Development of HLA antibodies after previous treatment with ASCs in the salivary glands as part of MESRIX-I, MESRIX-II or MESRIX-III.
|
Gentagen behandling med fedt-deriverede mesenkymale stamceller til patienter som tidligere har modtaget stamceller som led i MESRIX-I, MESRIX-II eller MESRIX-III. Formålet er at undersøge om gentagen behandling med donorstamceller har bedre effekt på spytkirtelfunktionen end en enkelt behandling. Inklusionskriterier. 1. tidligere behandling med ASCs i MESRIX-I, MESRIX-II or MESRIX-III. 2. WHO Performance status (PS) 0-1 3. Alder mellem 18-75 år 4. 2 års follow up uden recidiv 5. informeret samtykke
Ekstra eksklusionkrietrium: 1. udvikling af HLA antistoffer efter tidligere behandling med ASCs i MESRIX-I, MESRIX-II or MESRIX-III.
|
|
E.3 | Principal inclusion criteria |
Previous radiotherapy for head and neck cancer 2 years follow-up without recurrence Clinically hyposalivation: unstimulated salivary flow < 0.2ml /ml and above 0.05 ml/min Informed consent Grade 1-3 Xerostomia evaluated by the UKU side effect rating scale Age 18-75 WHO performance score 0-1
|
Tidligere strålebehandling for hovedhalskræft 2 års opfølgning uden recidiv Klinisk mundtørhed og nedsat funktion af de store spytkirtler-evalueret ved anerkendt screeningsmetode: unstimuleret spyt flow < 0.2ml /ml og > 0.05 ml/min Informeret samtykke underskrevet Alder 18-75 WHO performance score 0-1
|
|
E.4 | Principal exclusion criteria |
Any cancer in the previous 2 years ( not including OPSCC and basocellular carcinoma) Smoking within the last 6 months Xerogenic medications within the last 3 months Any current or previous other diseases in the salivary glands (Sjögrens syndrome, Sialolithiasis etc.) Pregnancy or planned pregnancy with the next 2 years Breastfeeding Any other disease/condition juged by the investigator to be grounds for exclusion |
Kræft af hvilken som helst type de seneste 2 år ( fraset mundsvælgkræft og basalcellehudkræft) Medicinsk behandling af mundtørhed Andre spytkirtel sygdomme eller tidligere operation på spytkirtlerne Graviditet eller planlagt graviditet inden for de næste 2 år Igangværende amning Anden sygdom som vurderes uhensigtsmæssigt i forhold til risici
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in unstimulated salivary flow rate
|
Ændring i ustimuleret spytsekretion |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
4 months and 12 months after intervention |
Ændring efter 4 og 12 måneder efter intervention |
|
E.5.2 | Secondary end point(s) |
1. Safety 2. Change in quality of life. 3. Change in saliva flow rate assessed by sialometri 4. Immune response to allogeneic ASC. 5. Change in the composition of saliva 6. Change in salivary gland function at four months, 1 year and 2 years after repeated treatment, measured by an increase in unstimulated and stimulated whole SFR. 7. Change in quality of life after repeated treatment. Evaluated by a decrease in complaints of xerostomia as evaluated by two patient questionnaires (EORTC QLQ Module for H&N-35and XQ) at four months, 1 year and 2 years. 8. Change in the composition of saliva after four months, 1 year and 2 years after repeated treatment.
|
1. Sikkerhed 2. Ændring i livskvalitet 3. Ændirng i spytproduktionen målt ved sialometri 4. Immunrespons sekondært til behandling med allogene fedt-derivederede stamceller 5. Ændring i spyttets sammensætning (spyttets kvalitet) 6. Ændring i spytkirtel funktion efter gentagen behandling med stamceller efter 4 måneder, 1 år og 2 år. 7. Ændring i livskvalitet efter gentagen behandling. Vurderes ved et fald i klager vedrørende xerostomi i spørgeskemaerne EORTC QLQ Module for H&N-35and XQ efter 4 måender, 1 år og 2 år. 8. Ændring i spytsammensætningen efter gentagen behandling målt efter 4 måneder, 1 åt og 2 år. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Blood samples 4 and 12 months after intervention. For repeated treatment also after 24 months. Quality of life questionnaires after 4 and 12 months after intervention. For repeated treatment also after 24 months. Sialometri after 4 and 12 months after intervention. For repeated treatment also after 24 months. |
Blodprøver 4 og 12 måneder efter intervention. For gentagen behandling også efter 24 måneder. Livskvalitetsspørgeskemaer 4 og 12 måneder efter intervention. For gentagen behandling også efter 24 måneder. Sialometri 4 og 12 måneder efter intervention.For gentagen behandling også efter 24 måneder. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
For delstudie vedr gentagen behandling er der ikke nogen blinding, radnomisering eller placebokontro |
For sub-study adressing repeated treatment there is no blinding, randomization or placebo-control. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
For delstudie vedr gentagen behandling er der ikke nogen blinding, radnomisering eller placebokontro |
For sub-study adressing repeated treatment there is no blinding, randomization or placebo-control. |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit last subject |
Sidst besøg, sidste deltager |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |